Pfizer has turned to Blackstone for up to $1.5B to bankroll clinical development of berobenatide, a monthly GLP-1 program sourced from Metsera, acquired last year. The arrangement is positioned to support the obesity pipeline as the regimen advances into late-stage testing. The reported funding underscores how large-cap pharma continues to externalize or ring-fence capital for late-stage risk and manufacturing readiness, particularly in crowded cardiometabolic categories. For biotech operators, it also reflects how platform and molecule licensing deals are increasingly coupled with structured financing. As berobenatide targets longer dosing intervals, the sponsor’s trial funding could shape pacing for pivotal readouts and may influence competitive dynamics against other monthly or ultra-long-acting GLP-1 candidates.